SCOTUS suggests willingness to finally tackle patent enablement standard
The US Supreme Court seeks Solicitor General’s input on whether take up controversial section 112 questions
The US Supreme Court seeks Solicitor General’s input on whether take up controversial section 112 questions
The INPI harnessed examination work done abroad as well as cutting-edge technology to reduce pileup of applications by 80%
Japan’s Maxell has been hit with court actions and patent invalidations in China by lithium ion battery supplier ATL
The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics
11 February 2021
Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary
04 February 2021
Two of country’s top industrials got successful results in the market that constitutes their number one business challenge
03 February 2021
South Korean PM’s comments show that IP enforcement does not happen in a vacuum
01 February 2021
Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system
21 January 2021
Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year
19 January 2021
While boosting transparency, the many difficulties faced by life sciences innovators when applying for protection in the country are not addressed
14 January 2021
As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.
22 December 2020
There is no clear stand-out in what is a highly interconnected industry. Instead a host of companies all rank as innovation leaders
18 December 2020
Failures to update IP management following the New Year could be costly for life sciences businesses
17 December 2020
Get unlimited access to all IAM content